Company / Return on Equity (ROE)
Arcutis Biotherapeutics, Inc. Return on Equity (ROE) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-8.5%
FY2025
5-year range
-295.7% / -8.5%
FY2021-FY2025
Trend
+90.4%
vs FY2024
Sector context
#59 of 190
Health Care
What the data says
Arcutis Biotherapeutics, Inc. reports negative total equity of -8.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-8.5% in FY2025 with a 5-year CAGR of +41.6%.
Improved from -295.7% to -8.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +140.1pp
- 5-Year Change
- +41.6pp
- 10-Year Change
- -
Sector benchmark
#59 of 190 in Health CareTop 31% of 190This company -8.5% Sector average -50.4%
▼
+83.1% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 90.4% year-over-year.
- Currently 41.9pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -8.5% | +90.4% |
| FY2024 | -88.9% | +69.9% |
| FY2023 | -295.7% | -98.9% |
| FY2022 | -148.6% | -114.4% |
| FY2021 | -69.3% | -38.3% |
| FY2020 | -50.1% | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026